Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of celecoxib when given
together with erlotinib in treating former smokers with stage IIIB, stage IV, recurrent, or
progressive non-small cell lung cancer. Celecoxib and erlotinib may stop the growth of tumor
cells by blocking the enzymes necessary for their growth.